Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 5/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3075654 | 0.82 | SLC6A2 (0.47) | SLC6A2ABCG2ABCB1RNASE1SHBG | |
| SCHEMBL18670788 | 0.81 | TK2 (0.56) | TK2SLC6A2ABCG2ABCB1RNASE1 | |
| SCHEMBL3082773 | 0.79 | TK2 (0.47) | TK2ABCG2ABCB1 | |
| SCHEMBL9745089 | 0.77 | ABCG2 (0.53) | TK2SLC6A2ABCG2ABCB1RNASE1 | |
| SCHEMBL3078239 | 0.76 | ALDH1A1 (0.42) | RNASE1 | |
| SCHEMBL3075364 | 0.76 | TK2 (0.43) | TK2ABCG2ABCB1 | |
| SCHEMBL11575184 | 0.75 | SLC6A2 (0.61) | TK2SLC6A2ABCG2RNASE1 | |
| SCHEMBL3079656 | 0.75 | TOP2A (0.42) | RNASE1 | |
| SCHEMBL11575187 | 0.75 | SLC6A2 (0.61) | TK2SLC6A2ABCG2RNASE1 | |
| SCHEMBL3082760 | 0.73 | TK2 (0.64) | TK2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | TK2 34/4885SLC6A2 858/4885ABCG2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.